Arsenic trioxide increases TRAILR2 expression and sensitizes GBM cells to TRAIL without affecting cFLIP or AKT [338]; other agents acting to similarly increase TRAILR1/R2 also sensitize GBM cells to TRAIL [408]. The gene discussed is TNFSF10; the disease is glioblastoma.